Pelthos Therapeutics Inc(PTHS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -26.36 | Insider Own | 55.98% | Shs Outstand | 3.7M | Perf Week | -29.27% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | 73.41% | Insider Trans | 1.41% | Shs Float | 1.7M | Perf Month | -31.76% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -3.08 | Inst Own | 43.15% | Short Float | 8.42% | Perf Quarter | -43.67% |
| Income | -0.09B | P/S | 1.28 | EPS this Y | 29.4% | Inst Trans | 1.94% | Short Ratio | 2.38 | Perf Half Y | -41.93% |
| Sales | 0.04B | P/B | - | EPS next 5Y | - | ROA | -124.96% | Short Interest | 0.14M | Perf YTD | -53.23% |
| Book/sh | -0.4 | P/C | 2.26 | EPS past 3/5Y | -75.48% -82.26% | ROE | -881.53% | 52W High | -61.33% ($37.50) | Perf Year | -54.69% |
| Cash/sh | 6.42 | P/FCF | - | Sales past 3/5Y | - 142.58% | ROIC | -121.74% | 52W Low | -4.61% ($15.20) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -42.78% | Gross Margin | 66.8% | Volatility(W/M) | 9.97% 6.58% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.4 | Sales Y/Y TTM | - | Oper. Margin | -133.42% | ATR (14) | 1.41 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.31 | EPS Q/Q | -22.87% | Profit Margin | -199.5% | RSI (14) | 23.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | Sales Q/Q | - | SMA20 | -26.05% ($19.61) | Beta | 3.19 | Target Price | $49.57 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -34.38% ($22.1) | Rel Volume | 1.23 | Prev Close | $15.2 |
| Employees | 92 | LT Debt/Eq | - | EPS/Sales Surpr. | -134.87% 2.84% | SMA200 | -40.58% ($24.4) | Avg Volume(3M) | 0.06M | Price | $14.5 |
| IPO | 2024/2/16 | Option/Short | No/Yes | Trades | 627 | Volume | 73,234 | Change | -4.61% |
💊 Peltos Therapeutics (PTHS) is a US-based biotech company in the healthcare sector. It is a micro-cap pharmaceutical firm focused on developing and commercializing new drugs, primarily in the dermatology and specialty therapeutics areas, with an emphasis on building a pipeline targeting diseases with unmet medical needs. Due to its micro-cap biotech nature, its valuation is heavily driven by clinical progress and regulatory approvals.
Over the past 1 year, on the lower side
61% below its 1-year high.
Traded about as much as usual. That is 123% of its average volume.
PTHS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +29.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $128. Peers typically go for $1,034.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 43.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #405 of 594 in the industry
Based on market cap of $56M.
CLNN#403 Clene Inc $56M PER - 
XBIT#404 XBiotech Inc $56M PER - PTHS#405 Pelthos Therapeutics Inc $56M PER - 
BOLD#406 Boundless Bio Inc $55M PER - 
HYFT#407 MindWalk Holdings Corp $55M PER - 
FAQ
What kind of company is PTHS?
PTHS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PTHS?
The market cap of PTHS is approximately $56M, ranking 4,794 within its sector.
What is the 52-week high and low for PTHS?
PTHS has recorded a 52-week high of $37.50 and a low of $15.20.
